GRPR and neoplasm: NeoBOMB1, labeled with Ga-68 (for PET), In-111 (for SPECT), or Lu-177 (for PRRT) showed promising theranostic profiles during preclinical evaluation, characterized by high receptor affinity and cell-uptake efficiency in vitro together with high metabolic stability and high and prolonged tumor uptake in GRPR-expressing tumors in vivo [34,70,71].